These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34777372)

  • 1. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
    Chen L; Zhou Q; Liu J; Zhang W
    Front Immunol; 2021; 12():759565. PubMed ID: 34777372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
    Xiao X; Mo H; Tu K
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma.
    Huo J; Wu L; Zang Y
    Med Sci Monit; 2020 Sep; 26():e925494. PubMed ID: 32945289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
    Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
    Front Immunol; 2022; 13():861525. PubMed ID: 35355983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
    Xu Q; Wang Y; Huang W
    Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
    Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
    Huo J; Wu L; Zang Y
    J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
    Lei H; Xiang T; Zhu H; Hu X
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
    Ruiz de Galarreta M; Bresnahan E; Molina-Sánchez P; Lindblad KE; Maier B; Sia D; Puigvehi M; Miguela V; Casanova-Acebes M; Dhainaut M; Villacorta-Martin C; Singhi AD; Moghe A; von Felden J; Tal Grinspan L; Wang S; Kamphorst AO; Monga SP; Brown BD; Villanueva A; Llovet JM; Merad M; Lujambio A
    Cancer Discov; 2019 Aug; 9(8):1124-1141. PubMed ID: 31186238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
    Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
    Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
    Akasu M; Shimada S; Kabashima A; Akiyama Y; Shimokawa M; Akahoshi K; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Sci Rep; 2021 Aug; 11(1):16732. PubMed ID: 34429454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
    Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.